Sino Biopharmaceutical Temettü
Temettü kriter kontrolleri 0/6
Sino Biopharmaceutical is a dividend paying company with a current yield of 1.67%.
Anahtar bilgiler
1.7%
Temettü verimi
0.9%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | 2.5% |
| Gelecekteki Temettü Verimi | 2.6% |
| Temettü Büyümesi | 14.1% |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | HK$0.060 |
| Ödeme oranı | 47% |
Son temettü güncellemeleri
Recent updates
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar
Oct 02
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
Sep 02Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?
Jul 12Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings
Apr 21What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 20Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon
Dec 18Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate
Nov 17We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?
May 26Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: 1177 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.
Büyüyen Temettü: 1177 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.
Piyasaya Karşı Temettü Getirisi
| Sino Biopharmaceutical Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (1177) | 1.7% |
| Pazarın Alt %25'i (HK) | 3.2% |
| Pazarın En İyi %25'i (HK) | 7.9% |
| Sektör Ortalaması (Pharmaceuticals) | 3.7% |
| Analist tahmini (1177) (3 yıla kadar) | 2.6% |
Önemli Temettü: 1177's dividend (1.67%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (3.25%).
Yüksek Temettü: 1177's dividend (1.67%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.92%).
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: 1177 is not paying a notable dividend for the Hong Kong market.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: 1177 is not paying a notable dividend for the Hong Kong market.